FARE Clinical Trial Finder

Simplify your search for a clinical trial and help researchers discover new therapies. The FARE Clinical Trial Finder links patients with food allergy and healthy, non-patient volunteers to actively recruiting food allergy studies.

Immune and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy

Study Purpose

The primary objective of this study is to determine whether allowing ingestion of sub-threshold amounts of peanut in those with a high threshold (tolerate at least 143 mg peanut protein on supervised double-blind, placebo-controlled oral food challenge [DBPCFC]) will be associated with attaining even higher thresholds over time in children with high threshold peanut allergy compared to those avoiding peanut. The secondary clinical objectives include assessing the development of sustained unresponsiveness (SU, a surrogate term for tolerance without daily ingestion), effects on quality of life, and safety compared to those avoiding peanut. Additionally, this study will phenotype the allergic response to peanut based on threshold and response to exposure. Mechanistic study objectives will determine the immune and molecular basis of the high threshold endotype, identify predictors of response to exposure, and determine mechanisms and biomarkers of remission.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 4 Years - 14 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

-Subject and/or parent guardian must be able to understand and provide informed consent. Inclusion criteria for screening DBPCFC:
  • - Age 4-14 years - either sex - any race, any ethnicity - who are enrolled while strictly avoiding peanut - have a history of sensitization (detectable peanut IgE >0.35 kUA/L) Inclusion criteria for randomization: - On screening DBPCFC are able to ingest >= 143 mg peanut protein but < 5043 mg peanut protein.
  • - All children will have documented consent and assent as is appropriate for age.

Exclusion Criteria:

Individuals who meet any of these criteria are not eligible for enrollment as study participants:
  • - Inability or unwillingness of a participant to give written informed consent or comply with study protocol - Serum peanut-specific IgE antibody level > 50 kUA/L - Recent (within the past 2 years) life-threatening (grade 3) anaphylactic reaction to peanut.
  • - Any disorder in which epinephrine is contraindicated such as known hypertension or cardia rhythm disorders.
  • - History of chronic disease requiring therapy (other than asthma, atopic dermatitis, rhinitis).
  • - On a build-up phase of any allergen immunotherapy.
  • - Current uncontrolled or moderate to severe asthma as defined by at least one of the following: 1.
FEV1 value <80% predicted (only for participants age 7 years or older and are able to perform spirometry 2. ACT or cACT < 20 3. >Step 3 controller therapy as defined for children 0-4, 5-11 and >=12 years of age by EPR-3 tables 4. Use of steroid medications in the following manners: 1. history of daily oral steroid dosing for >1 month during the past year, 2. having 1 burst or steroid course within the past 6 months, or 3. having >1 burst oral steroid course within the past 12 months. 5. Asthma requiring >1 hospitalization in the past year for asthma or >1 ED visit in the past 6 months for asthma, or any prior intubation/mechanical ventilation for asthma/wheezing.
  • - Gastrointestinal eosinophilic disorders, esophagitis, gastroenteritis.
  • - Use of short-acting antihistamines (diphenhydramine, etc.) more than one time within 3 days prior to DBPCFC or skin testing.
*
  • - Use of medium-acting antihistamines (hydroxyzine, loratadine, etc.) more than one time within 7 days of DBPCFC or skin testing.
*
  • - Use of systemic steroid medications (IV, IM or oral) for indications other than asthma for > 3 weeks within the past 6 months - Use of beta-blockers (oral), (ACE) inhibitors, angiotensin-receptor blockers or calcium channel blockers.
  • - Participation in any trials of therapeutic interventions for food allergy in the past year.
  • - Therapy with anti-IgE or other biologics, including within 1 year of enrollment.
  • - Use of investigational drugs within 52 weeks of participation.
  • - Allergy to all of the following: oat, rice, corn, tapioca.
  • - Pregnancy - Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
*Any subject meeting these criteria during the visits can be rescheduled for the oral food challenge or prick skin testing.*

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03907397
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Scott Sicherer
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Scott Sicherer, MD
Principal Investigator Affiliation Icahn School of Medicine at Mount Sinai
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

OtherNIH
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Food Allergy, Peanut Allergy

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Icahn School of Medicine at Mount Sinai, New York, New York

Status

Recruiting

Address

Icahn School of Medicine at Mount Sinai

New York, New York, 10029

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.